Eli Lilly and CoFRA:LLY0 +6.45%98 PB Ratio is 32.04 as of Jun. 27, 2026, which is 4% below its 10-year median of 33.23. GuruFocus rates FRA:LLY0 with a GF Score™ of 98/100 and a GF Value™ of €30.80 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 98.7% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Eli Lilly and Co's share price is €26.40. Eli Lilly and Co's Book Value per Share for the quarter that ended in Mar. 2026 was €0.82. Hence, Eli Lilly and Co's PB Ratio of today is 32.04.
The historical rank and industry rank for Eli Lilly and Co's PB Ratio or its related term are showing as below:
FRA:LLY0'
s PB Ratio Range Over the Past 10 Years
Min: 4.79 Med: 33.23 Max: 65.3
Current: 34.6
During the past 13 years, Eli Lilly and Co's highest PB Ratio was 65.30. The lowest was 4.79. And the median was 33.23.
FRA:LLY0's PB Ratio is ranked worse than 98.7% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs FRA:LLY0: 34.60
During the past 12 months, Eli Lilly and Co's average Book Value Per Share Growth Rate was 98.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 38.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 32.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Eli Lilly and Co was 60.30% per year. The lowest was -40.20% per year. And the median was 6.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Eli Lilly and Co PB Ratio Related Terms
Eli Lilly and Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Eli Lilly and Co (FRA:LLY0) has a PB Ratio of 32.04 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eli Lilly and Co and its competitors. This is near median its historical median of 33.23. Over the past decade, Eli Lilly and Co's PB Ratio has ranged from 4.79 to 65.30. According to the industry distribution chart, Eli Lilly and Co ranks #910 out of 922 companies in the Drug Manufacturers industry, placing it in the top 98.7%.
Is Eli Lilly and Co's PB Ratio too high?
Eli Lilly and Co's current PB Ratio of 32.04 is near median its 10-year median of 33.23. Over the past 10 years, this metric has ranged from a low of 4.79 to a high of 65.30. The Drug Manufacturers industry median PB Ratio is 1.83. Eli Lilly and Co's value of 32.04 is 1655.6% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #910 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's PB Ratio compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #910 out of 922 companies for PB Ratio. This places Eli Lilly and Co in the lower half of its industry. The industry median PB Ratio is 1.83. Eli Lilly and Co's value of 32.04 is 1655.6% above this benchmark. Historically, Eli Lilly and Co's own PB Ratio has ranged from 4.79 to 65.30 over the past decade. While the company's 10-year median is 33.23 vs. the industry median of 1.83, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current PB Ratio of 32.04 is 1655.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current PB Ratio is 32.04, which is near median its own 10-year median of 33.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (FRA:LLY0) is currently considered Modestly Undervalued. The stock's GF Value™ is €30.80, compared to a current price of €26.40 — trading 14.3% below its estimated fair value. The current PB Ratio is 32.04, which is near median its 10-year median of 33.23 and 1655.6% above the Drug Manufacturers industry median of 1.83. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Eli Lilly and Co (FRA:LLY0), the current PB Ratio is 32.04 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (FRA:LLY0) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €26.40 is trading 14.3% below its estimated GF Value™ of €30.80.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for FRA:LLY0:
PB Ratio: 32.04 (near median its 10-year median of 33.23)
GF Value™: €30.80 vs. price of €26.40 (14.3% below fair value)
Industry Position: 1655.6% above the Drug Manufacturers median (#910 of 922)
No single metric tells the full story. See the FRA:LLY0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score
Get the complete analysis for FRA:LLY0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LLY0 has been successfully added to your 
